Prescription Drug Supply Chain Pricing Transparency Act

This bill (S 3751) mandates a study by the Government Accountability Office (GAO) into how fees and payments are structured within the prescription drug supply chain. The GAO must examine compensation models used by intermediaries like pharmacy benefit managers, drug wholesalers, manufacturers, and others - specifically focusing on how fees tied to drug prices (e.g., percentage-based payments) may create conflicts of interest or influence pricing decisions. The study will analyze trends, business models, and potential impacts on drug costs, with a report due to Congress within two years of the bill’s enactment. It does not change current laws but aims to inform future policy by documenting these payment structures.